hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06292260, orgStudyIdInfo id: 2020-2054-2, briefTitle: Digital Toolkit for Skin Diseases in LMICs: Part 2, acronym: MIND-the-SKIN2, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2026-05-31, completionDateStruct date: 2026-05-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Tulane University, class: OTHER, collaborators name: Hope Commission International, collaborators name: Institut Pasteur of Cote d'Ivoire, collaborators name: Institut Raoul Follereau, collaborators name: Centre Suisse de Recherches Scientifiques en Cote d'Ivoire, collaborators name: Tokyo Medical and Dental University, descriptionModule briefSummary: Impact evaluation of eSkinHealth in improving case detection of skin NTDs and treatment outcomes in rural and urban settings, conditionsModule conditions: Skin Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: mHealth app, outcomesModule primaryOutcomes measure: Number of cases of each skin NTD (neglected tropical disease) and other skin conditions as compared to the pre-intervention, secondaryOutcomes measure: Case confirmation rate for each skin NTD (neglected tropical disease) and other skin conditions by dermatologists, secondaryOutcomes measure: Number of days from registry to confirmatory diagnosis, secondaryOutcomes measure: Feasibility, usability, and effectiveness of the surveillance approach using eSkinHealth app, secondaryOutcomes measure: Capacity building and effectiveness of training, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hope Commission International, status: RECRUITING, city: Abidjan, country: Côte D'Ivoire, contacts name: Aubin Yao, MS, role: CONTACT, email: aubin@hopecommission.org, contacts name: Eric-Herman N'da Kouakou, role: CONTACT, email: ekouakou@hopecommission.org, contacts name: Bamba Vagamon, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 5.30966, lon: -4.01266, hasResults: False
protocolSection identificationModule nctId: NCT06292247, orgStudyIdInfo id: A0503023, briefTitle: Effectiveness of CBT and APT on Managing Child Anxiety in Dental Office, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-10-23, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: This study was conducted to the Effectiveness of Cognitive Behavioral Therapy and Auricular Plaster Therapy on Managing Child Anxiety in Dental Office., conditionsModule conditions: Dental Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Group 1 (CBT) Group 2 (APT) Group3 (control TSD), primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Cognitive behavioral therapy, interventions name: Auricular plaster therapy, interventions name: Tell Show Do, outcomesModule primaryOutcomes measure: Venham Clinical Anxiety Scale, primaryOutcomes measure: Heart Rate to detect the anxiety., primaryOutcomes measure: RMS-Self Pictorial scale to detect the anxiety., secondaryOutcomes measure: Parental acceptance of the behavior management technique, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 7 Years, stdAges: CHILD, contactsLocationsModule locations facility: Faculty of dentistry, city: Mansoura, state: Dakahlia, zip: 35511, country: Egypt, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06292234, orgStudyIdInfo id: OMFS, briefTitle: Patient Specific Implant Versus Miniplates for Advancement of Hypoplastic Maxilla, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Distraction osteogenesis is the treatment of choice in management of severe maxillary anteroposterior deficiency allowing for a progressive bone generation and simultaneous expansion of the surrounding scarred soft tissue \& better long-term stability \& less relapse rate., conditionsModule conditions: Cleft Lip and Palate, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel randomized controlled trial with 1:1 allocation ratio and superiority framework, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: single blinded clinical trial, whoMasked: PARTICIPANT, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: PSI, interventions name: Conventional miniplates, outcomesModule primaryOutcomes measure: Distraction effectiveness, secondaryOutcomes measure: Velopharyngeal insufficiency, secondaryOutcomes measure: Speech, secondaryOutcomes measure: Operative time, secondaryOutcomes measure: Wound dehiscence, secondaryOutcomes measure: Infection, secondaryOutcomes measure: Nerve affection, secondaryOutcomes measure: Screw loosening, secondaryOutcomes measure: Overall complications, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06292208, orgStudyIdInfo id: IBD0333-101, briefTitle: A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-02, primaryCompletionDateStruct date: 2029-12-31, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: SUNHO（China）BioPharmaceutical CO., Ltd., class: INDUSTRY, descriptionModule briefSummary: Primary Objectives Dose escalation phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the maximum tolerated dose (MTD), extended recommended dose (DRDE), and/or dose limiting toxicity (DLT).Dose expansion phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the recommended Phase 2 dose (RP2D).Clinical exploration phase To evaluate the preliminary efficacy of IBD0333 in patients with specific tumor.Secondary objectives Dose escalation phase \& Dose expansion phase To evaluate the pharmacokinetic (PK) of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma; To evaluate the immunogenicity of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma; To evaluate the preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma.Clinical exploration Phase To evaluate the safety and tolerability of IBD0333 in patients with specific tumor; To evaluate the immunogenicity of IBD0333 in patients with specific tumor. Exploratory Objectives To explore biomarkers in blood and tissue that predict potential efficacy of IBD0333., conditionsModule conditions: MTD, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: IBD0333, outcomesModule primaryOutcomes measure: MTD, primaryOutcomes measure: DRDE, primaryOutcomes measure: Dose limiting toxicity (DLT), primaryOutcomes measure: RP2D, primaryOutcomes measure: ORR, secondaryOutcomes measure: pharmacokinetic parameters, secondaryOutcomes measure: pharmacokinetic parameters, secondaryOutcomes measure: pharmacokinetic parameters, secondaryOutcomes measure: pharmacokinetic parameters, secondaryOutcomes measure: ADA, secondaryOutcomes measure: ORR, secondaryOutcomes measure: DCR, secondaryOutcomes measure: DoR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: Frequency of adverse events (AEs) and SAEs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06292182, orgStudyIdInfo id: 160802, secondaryIdInfos id: 332942, type: OTHER, domain: IRAS, secondaryIdInfos id: 58964, type: OTHER, domain: CPMS, briefTitle: Red Light Ptosis Proof-of-Concept, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University College, London, class: OTHER, collaborators name: Moorfields Eye Hospital NHS Foundation Trust, descriptionModule briefSummary: This study tests a new treatment to help with droopy eyelids (ptosis) and eye movement problems (squint) in children and young people with genetically confirmed mitochondrial conditions - using red-light.We use a torch to shine a red light through the closed eyelid for 3 minutes a day. The study will run for 18 months.We believe that this treatment could help strengthen the muscle in the eyelid to make it easier to open the eyes, and could also help some children with squint., conditionsModule conditions: Mitochondrial Diseases, conditions: Blepharoptosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Near-infrared light, outcomesModule primaryOutcomes measure: Palpebral fissure width, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Moorfields Eye Hospital NHS Foundation Trust, status: RECRUITING, city: London, zip: EC1V 2PD, country: United Kingdom, contacts name: Annegret H Dahlmann-Noor, PhD, role: CONTACT, phone: 020 7253 3411, email: annegret.dahlmann-noor@nhs.net, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06292143, orgStudyIdInfo id: EU101136769-CLIN2, briefTitle: AI4HOPE Dementia Care Planning Pilot Study 2 ( AI4HOPE2), acronym: AI4HOPE-P2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-07, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Bonn, class: OTHER, collaborators name: University College Cork, collaborators name: University of Leeds, collaborators name: Fundacion Intras, collaborators name: Universidade do Porto, collaborators name: University Medical Centre Maribor, descriptionModule briefSummary: This pilot study will test a digital care planning decision support system for patients with dementia., conditionsModule conditions: Dementia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Feasibility study, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Advance Care Planning Toolkit, outcomesModule primaryOutcomes measure: Ease of use of digital platform, primaryOutcomes measure: Effect of digital platform on documentation of advance care planning, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Bonn, city: Bonn, zip: 53127, country: Germany, geoPoint lat: 50.73438, lon: 7.09549, hasResults: False
protocolSection identificationModule nctId: NCT06292104, orgStudyIdInfo id: STU-2023-0589, secondaryIdInfos id: 1R01HL166272-01A1, type: NIH, link: https://reporter.nih.gov/quickSearch/1R01HL166272-01A1, briefTitle: Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-05, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2029-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: University of Texas Southwestern Medical Center, class: OTHER, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), descriptionModule briefSummary: This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities., conditionsModule conditions: Postural Orthostatic Tachycardia Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 350, type: ESTIMATED, armsInterventionsModule interventions name: multimodal diagnostic testing, outcomesModule primaryOutcomes measure: Phenotyping POTS, primaryOutcomes measure: Natural history, primaryOutcomes measure: Natural history, eligibilityModule sex: ALL, minimumAge: 14 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UT Southwestern Medical Center, status: RECRUITING, city: Dallas, state: Texas, zip: 75208, country: United States, contacts name: Steven Hopkins, role: CONTACT, phone: 214-648-9275, email: steve.hopkins@utsouthwestern.edu, contacts name: Steven Hopkins, role: CONTACT, phone: 2146489275, email: steve.hopkins@utsouthwestern.edu, contacts name: Steven Vernino, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False
protocolSection identificationModule nctId: NCT06292091, orgStudyIdInfo id: Ur_ABD_PK, briefTitle: A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-03-27, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Seoul National University Hospital, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the effect of urine acid-base disequilibrium on the pharmacokinetics of captopril in healthy male volunteers., conditionsModule conditions: Hypertension, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: Captopril 12.5 Mg, interventions name: Sodium bicarbonate 4 G, interventions name: Torsemide 20 MG, outcomesModule primaryOutcomes measure: AUClast of captopril, primaryOutcomes measure: Cmax of captopril, secondaryOutcomes measure: AUCinf of captopril, secondaryOutcomes measure: Tmax of captopril, secondaryOutcomes measure: t1/2 of captopril, secondaryOutcomes measure: CL/F of captopril, secondaryOutcomes measure: Vd/F of captopril, secondaryOutcomes measure: fe of captopril, secondaryOutcomes measure: urine pH, secondaryOutcomes measure: Safety parameters, eligibilityModule sex: MALE, minimumAge: 19 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Seoul National University Hospital, city: Seoul, zip: 03080, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06292078, orgStudyIdInfo id: 1R01DA059401-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1R01DA059401-01, secondaryIdInfos id: 1R01DA059401-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1R01DA059401-01, briefTitle: Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA), acronym: ISLA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2028-08, completionDateStruct date: 2028-08, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University of Oregon, class: OTHER, collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: This project will test the effectiveness of the Inclusive Skill-building Learning Approach (ISLA) in reducing the use of exclusionary discipline, improving teacher practice and student outcomes, and decreasing substance misuse using a randomized controlled trial in 60 middle schools across six states., conditionsModule conditions: Opioid Misuse, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 5076, type: ESTIMATED, armsInterventionsModule interventions name: Instructional Skill-Building Learning Approach (ISLA), outcomesModule primaryOutcomes measure: Frequency and Duration of Use of Office Discipline Referrals, In-School Suspension, and Out-of-School Suspension, primaryOutcomes measure: Engagement vs. Disaffection with Learning Student-report, primaryOutcomes measure: Inclusive Teaching Practices, primaryOutcomes measure: School Climate Survey- Student, primaryOutcomes measure: School Climate- Teacher, primaryOutcomes measure: Student-Teacher Relationships, primaryOutcomes measure: Opioid and Other Substance Misuse, primaryOutcomes measure: Student Internalizing Behaviors, primaryOutcomes measure: Student Externalizing Behaviors, primaryOutcomes measure: ISLA Acceptability, primaryOutcomes measure: ISLA Implementation Fidelity, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06292052, orgStudyIdInfo id: NSCLC-TDLN-001, briefTitle: Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness, statusModule overallStatus: RECRUITING, startDateStruct date: 2017-01-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, collaborators name: Jiangmen Central Hospital, collaborators name: Henan Cancer Hospital, descriptionModule briefSummary: The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness., conditionsModule conditions: Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 350, type: ESTIMATED, armsInterventionsModule interventions name: Immunotherapy, outcomesModule primaryOutcomes measure: Complete pathologic response, secondaryOutcomes measure: Major pathologic response, secondaryOutcomes measure: Complete pathologic response in lymph nodes, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen University Cancer Center, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510060, country: China, contacts name: Hao Long, MD, role: CONTACT, phone: +86-13802770989, email: longhao@sysucc.org.cn, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06292039, orgStudyIdInfo id: P0555788, secondaryIdInfos id: 2KL2TR001870, type: NIH, link: https://reporter.nih.gov/quickSearch/2KL2TR001870, briefTitle: Human-centered Injury Thrivorship Pathway for Survivors of Physical Trauma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-07, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: University of California, San Francisco, class: OTHER, collaborators name: National Center for Advancing Translational Sciences (NCATS), descriptionModule briefSummary: The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is:• Is the pathway appropriate, acceptable, and feasible to meet the medical and social needs of injury survivors?Injury survivors will be purposively sampled to enroll in the pathway and asked to participate in in-depth interviews and their use of pathway resources will be tracked., conditionsModule conditions: Injury Traumatic, conditions: Survivorship, conditions: Trauma Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Human-Centered Injury Thrivorship Pathway, outcomesModule primaryOutcomes measure: Early Implementation Outcomes - Acceptability, Appropriateness, Feasibility, secondaryOutcomes measure: Participant pathway resource utilization - type, secondaryOutcomes measure: Participant pathway resource utilization - frequency, secondaryOutcomes measure: Participant pathway resource utilization - duration, secondaryOutcomes measure: Participant pathway resource utilization - % utilized, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zuckerberg San Francisco General Hospital, city: San Francisco, state: California, zip: 94110, country: United States, contacts name: Marissa A Boeck, MD, MPH, role: CONTACT, phone: 415-502-4745, email: marissa.boeck@ucsf.edu, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False